Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts
Open Access
- 24 January 2014
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 8 (3), 656-668
- https://doi.org/10.1016/j.molonc.2014.01.008
Abstract
Introduction Improvement in the ability to target underlying drivers and vulnerabilities of high‐grade serous ovarian cancer (HG‐SOC) requires the development of molecularly annotated pre‐clinical models reflective of clinical responses. Methods We generated patient‐derived xenografts (PDXs) from consecutive, chemotherapy‐naïve, human HG‐SOC by transplanting fresh human HG‐SOC fragments into subcutaneous and intra‐ovarian bursal sites of NOD/SCID IL2Rγnull recipient mice, completed molecular annotation and assessed platinum sensitivity. Results The success rate of xenografting was 83%. Of ten HG‐SOC PDXs, all contained mutations in TP53, two were mutated for BRCA1, three for BRCA2, and in two, BRCA1 was methylated. In vivo cisplatin response, determined as platinum sensitive (progression‐free interval ≥100 d, n = 4), resistant (progression‐free interval n = 3) or refractory (n = 3), was largely consistent with patient outcome. Three of four platinum sensitive HG‐SOC PDXs contained DNA repair gene mutations, and the fourth was methylated for BRCA1. In contrast, all three platinum refractory PDXs overexpressed dominant oncogenes (CCNE1, LIN28B and/or BCL2). Conclusions Because PDX platinum response reflected clinical outcome, these annotated PDXs will provide a unique model system for preclinical testing of novel therapies for HG‐SOC.Keywords
Funding Information
- National Health and Medical Research Council
- Cancer Council Victoria
- Victorian Cancer Agency
- CRC for Cancer Therapeutics
- National Institute of Health
- Wendy Feuer Ovarian Cancer Research Fund (EMS)
This publication has 33 references indexed in Scilit:
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment StrategiesClinical Cancer Research, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian CancersPLOS ONE, 2011
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Unleashing the power of inhibitors of oncogenic kinases through BH3 mimeticsNature Reviews Cancer, 2009
- Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapyGynecologic Oncology, 2008
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesAmerican Journal of Human Genetics, 2007
- Development of a syngeneic mouse model for events related to ovarian cancerCarcinogenesis: Integrative Cancer Research, 2000